Home›News›Clinical Trials›NeoStem to Present its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23, 2010

NeoStem to Present its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23, 2010

NEW YORK, Sept. 22 /PRNewswire/ -- NeoStem, Inc. (NYSE
Amex: NBS) ("NeoStem" or
the "Company"), an international biopharmaceutical company with
operations in the U.S. and China,
today announced that the Company will be presenting its
Autologous Adult Stem Cell VSEL™ Technology for the
Treatment of Battlefield Wounds at The USU-HJF Military Medicine
Symposium in Washington DC,
September 23rd, 2010.

NeoStem has a worldwide exclusive license to VSEL™
Technology which uses very small embryonic-like stem cells, a
heterogeneous population of stem cells found in adult bone marrow
that have properties similar to those of embryonic stem cells.
NeoStem has shown that very small embryonic-like stem cells
can be mobilized into the peripheral blood, enabling a minimally
invasive means for collecting what NeoStem believes to be an
important population of stem cells that may have the potential to
achieve the positive benefits associated with embryonic stem cells
without the ethical or moral dilemmas or the potential negative
effects associated with embryonic stem cells.

The Center for Public-Private Partnerships at the Henry M.
Jackson Foundation for the Advancement of Military Medicine, along
with the USU (Uniformed Services University of
the Health Sciences), will present a symposium highlighting
important advances in military medicine. The event will bring
together a broad spectrum of participants, including
representatives of the Military Health System and military
leadership, federal agencies, private research institutions,
philanthropists and charitable foundations, representatives of
industry, and policymakers.

Panels will highlight advancements in research and clinical
care, including:

The state-of-the-science in regenerative medicine technologies
and potential applications for wounded warriors

The latest research on suicide prevention and traumatic stress
among military veterans

Community outreach to address psychological health challenges
faced by service members and their families

The event is intended to foster collaboration and expand
public-private partnerships to advance military medical research.
The program will include opportunities for discussion and
networking among participants.

The USU-HJF Military Medicine Symposium will be held on
Thursday, September 23, 2010, at the
Omni Shoreham Hotel located at 2500 Calvert Street, NW in
Washington, DC. NeoStem will
be exhibiting in the Blue Pre-Function Room its presentation on
"Autologous Adult Stem Cell Solutions to Battlefield Wounds: Future
Prospects for VSEL Technology". NeoStem's exhibit will be on
display throughout the day from 7:30 am to
6:30 pm.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based
therapies, pursuit of anti-aging initiatives and building of a
network of adult stem cell collection centers in the U.S. and
China that are focused on enabling
people to donate and store their own (autologous) stem cells for
their personal use in times of future medical need. The Company is
also the licensee of various stem cell technologies, including a
worldwide exclusive license to VSEL™ Technology which uses
very small embryonic-like stem cells, shown to have several
physical characteristics that are generally found in embryonic stem
cells, and is pursuing the licensing of other technologies for
therapeutic use. NeoStem's majority-controlled Chinese
pharmaceutical operation, Suzhou Erye, manufactures and distributes
generic antibiotics in China. For
more information, please visit: http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
the future of VSEL™ Technology and adult stem cells as a
viable treatment option, about which no assurances can be given.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in
the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 31,
2010 as well as other periodic filings made with the
Securities and Exchange Commission. The Company's further
development is highly dependent on future medical and research
developments and market acceptance, which is outside its
control.